US20220175876A1 - Angio-3 for treatment of retinal angiogenic diseases - Google Patents
Angio-3 for treatment of retinal angiogenic diseases Download PDFInfo
- Publication number
- US20220175876A1 US20220175876A1 US17/525,793 US202117525793A US2022175876A1 US 20220175876 A1 US20220175876 A1 US 20220175876A1 US 202117525793 A US202117525793 A US 202117525793A US 2022175876 A1 US2022175876 A1 US 2022175876A1
- Authority
- US
- United States
- Prior art keywords
- angio
- vegf
- retinal
- peptide
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 81
- 201000010099 disease Diseases 0.000 title claims abstract description 69
- 230000002207 retinal effect Effects 0.000 title claims abstract description 64
- 230000002491 angiogenic effect Effects 0.000 title claims abstract description 41
- 238000011282 treatment Methods 0.000 title description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 93
- 238000000034 method Methods 0.000 claims abstract description 62
- 239000000203 mixture Substances 0.000 claims description 58
- 238000002347 injection Methods 0.000 claims description 30
- 239000007924 injection Substances 0.000 claims description 30
- 238000002560 therapeutic procedure Methods 0.000 claims description 28
- 238000001990 intravenous administration Methods 0.000 claims description 25
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 11
- 208000002780 macular degeneration Diseases 0.000 claims description 11
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 10
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 9
- 201000000159 corneal neovascularization Diseases 0.000 claims description 9
- 238000010253 intravenous injection Methods 0.000 claims description 8
- JAJOFWABAUKAEJ-QTKMDUPCSA-N Thr-Pro-His Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O JAJOFWABAUKAEJ-QTKMDUPCSA-N 0.000 claims description 7
- 208000017442 Retinal disease Diseases 0.000 claims description 6
- 206010038923 Retinopathy Diseases 0.000 claims description 6
- 206010053648 Vascular occlusion Diseases 0.000 claims description 6
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 6
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 claims description 5
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 5
- 201000011190 diabetic macular edema Diseases 0.000 claims description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 77
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 77
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 76
- 210000001508 eye Anatomy 0.000 description 56
- 241000699670 Mus sp. Species 0.000 description 50
- 235000001014 amino acid Nutrition 0.000 description 36
- 229940024606 amino acid Drugs 0.000 description 34
- 102000004196 processed proteins & peptides Human genes 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 33
- 239000003814 drug Substances 0.000 description 28
- 108010081667 aflibercept Proteins 0.000 description 26
- 229940051306 eylea Drugs 0.000 description 25
- 231100000673 dose–response relationship Toxicity 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 21
- 229940079593 drug Drugs 0.000 description 20
- 230000003902 lesion Effects 0.000 description 20
- 230000033115 angiogenesis Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 230000035699 permeability Effects 0.000 description 17
- 230000035755 proliferation Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 14
- 210000001525 retina Anatomy 0.000 description 13
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 12
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 206010029113 Neovascularisation Diseases 0.000 description 11
- 210000002889 endothelial cell Anatomy 0.000 description 11
- 230000005012 migration Effects 0.000 description 11
- 238000013508 migration Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000008728 vascular permeability Effects 0.000 description 11
- 241000282693 Cercopithecidae Species 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 10
- 238000000692 Student's t-test Methods 0.000 description 10
- 238000013534 fluorescein angiography Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- -1 CM101 Chemical compound 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000002500 effect on skin Effects 0.000 description 9
- 238000012014 optical coherence tomography Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000001747 pupil Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000004263 retinal angiogenesis Effects 0.000 description 8
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 7
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 7
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000003527 anti-angiogenesis Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 102000058223 human VEGFA Human genes 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004243 retinal function Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 6
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 6
- 210000002867 adherens junction Anatomy 0.000 description 6
- 230000001772 anti-angiogenic effect Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 229940120638 avastin Drugs 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000013401 experimental design Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 230000003204 osmotic effect Effects 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 108010002321 Tight Junction Proteins Proteins 0.000 description 5
- 102000000591 Tight Junction Proteins Human genes 0.000 description 5
- 102000008790 VE-cadherin Human genes 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 108010018828 cadherin 5 Proteins 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 206010015866 Extravasation Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000785523 Homo sapiens Tight junction protein ZO-2 Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000013566 Plasminogen Human genes 0.000 description 4
- 108010051456 Plasminogen Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- VUSAEKOXGNEYNE-PBCZWWQYSA-N Thr-His-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O VUSAEKOXGNEYNE-PBCZWWQYSA-N 0.000 description 4
- 102100026637 Tight junction protein ZO-2 Human genes 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000003399 chemotactic effect Effects 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 230000036251 extravasation Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229930182817 methionine Chemical group 0.000 description 4
- 108010091858 peptide Q Proteins 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001578 tight junction Anatomy 0.000 description 4
- 208000006069 Corneal Opacity Diseases 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000011685 brown norway rat Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 231100000269 corneal opacity Toxicity 0.000 description 3
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 229940076783 lucentis Drugs 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000000649 photocoagulation Effects 0.000 description 3
- 230000004276 retinal vascularization Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229950003937 tolonium Drugs 0.000 description 3
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229960004791 tropicamide Drugs 0.000 description 3
- 229940072358 xylocaine Drugs 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000012936 Angiostatins Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 2
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003487 anti-permeability effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- GTKRFUAGOKINCA-UHFFFAOYSA-M chlorosilver;silver Chemical compound [Ag].[Ag]Cl GTKRFUAGOKINCA-UHFFFAOYSA-M 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000000599 controlled substance Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002571 electroretinography Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 2
- 238000002647 laser therapy Methods 0.000 description 2
- 210000001232 limbus corneae Anatomy 0.000 description 2
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000003518 stress fiber Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- GMKMEZVLHJARHF-UHFFFAOYSA-N 2,6-diaminopimelic acid Chemical compound OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N 5-hydroxylysine Chemical group NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 1
- 229920003319 Araldite® Polymers 0.000 description 1
- UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 201000002994 Dyschromatosis symmetrica hereditaria Diseases 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UMZHHILWZBFPGL-LOKLDPHHSA-N Glu-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O UMZHHILWZBFPGL-LOKLDPHHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000219774 Griffonia Species 0.000 description 1
- 108010016101 Griffonia simplicifolia lectins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- XIGFLVCAVQQGNS-IHRRRGAJSA-N His-Pro-His Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XIGFLVCAVQQGNS-IHRRRGAJSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010024404 Leukostasis Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
- OLNLSTNFRUFTLM-BYPYZUCNSA-N N-ethyl-L-asparagine Chemical compound CCN[C@H](C(O)=O)CC(N)=O OLNLSTNFRUFTLM-BYPYZUCNSA-N 0.000 description 1
- OLNLSTNFRUFTLM-UHFFFAOYSA-N N-ethylasparagine Chemical compound CCNC(C(O)=O)CC(N)=O OLNLSTNFRUFTLM-UHFFFAOYSA-N 0.000 description 1
- 108010065338 N-ethylglycine Proteins 0.000 description 1
- 208000032234 No therapeutic response Diseases 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010055666 Retinal neovascularisation Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 206010047555 Visual field defect Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960001232 anecortave Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002577 ophthalmoscopy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 210000001927 retinal artery Anatomy 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 230000004233 retinal vasculature Effects 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- YSMODUONRAFBET-WHFBIAKZSA-N threo-5-hydroxy-L-lysine Chemical compound NC[C@@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-WHFBIAKZSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
This disclosure provides methods of a method of treating a retinal angiogenic disease in a subject comprising administering an effective amount of an Angio-3 peptide.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/641,978, filed Aug. 31, 2018, which is a U.S. National Phase of International Application No. PCT/M2018/056685, filed Aug. 31, 2018, which claims priority to U.S. Patent Application No. 62/553,051, filed Aug. 31, 2017, the disclosure of which is hereby incorporated by reference in its entirety for purposes.
- The Sequence Listing written in file 101286_1283483_SEQ_LST.txt created on Nov. 9, 2021, containing 1,371 bytes, machine format IBM-PC, MS-Windows operating system, is hereby incorporated by reference in its entirety.
- Retinal angiogenic diseases include age-related macular degeneration, retinopathy, vascular occlusion, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization. Retinal angiogenic disease, e.g., age-related macular degeneration (AMD), is the most frequent cause of legal blindness in the elderly in industrialized countries (Van Leeuwen et al. (2003), European Journal of Epidemiology 18: 845-854). It is a heterogeneous disease, which is characterized by progressive loss of central, high acuity vision. For the patient it dramatically compromises quality of life, as they lose their ability to read, to recognize faces, and day-to-day tasks become major obstacles. According to the World Health Organization (WHO) a total of 30-50 million individuals are affected and about 14 million people are blind or severe visual impairment due to AMD (Gehrs et al., (2006) Annals of Medicine 38:450-471).
- The pathological process responsible for retinal angiogenic diseases is the formation of chaotically oriented and physiologically deficient new blood vessels under the retina, known as choroidal neovascularization (CNV). Although aging, oxidative stress, genetics and inflammation have all been described to contribute to the pathogenesis of CNV; angiogenesis is currently believed to be responsible for the final common pathway.
- Current treatment options for AMD include laser therapy, surgery to remove or destroy the abnormal blood vessels, and anti-angiogenic therapies, e.g., anti-vascular endothelial growth factor (“VEGF”), i.e., anti-VEGF therapies. These anti-angiogenic medications are typically injected into the vitreous body of the eye, which cause great discomfort and inconvenience to the patients. In addition, some patients have developed resistance to anti-VEGF therapy and are in need of other treatment options. Yang et al., Drug. Des. Devel. Ther. 2016: 10:1857-1867.
- Provided herein is a method of treating a retinal angiogenic disease in a subject. The methods include administering to the subject a pharmaceutically effective amount of a composition comprising a peptide having the sequence Thr Pro His Thr His Asn Arg Thr Pro Glu (SEQ ID NO:1). The composition can be administered to the subject orally, by intravenous injection, or by intravitreal injection, or by sublingual delivery wherein administration treats the retinal angiogenic disease in the subject.
- Optionally, the composition comprises 2 to 50 mg/kg body weight (Bwt) of the peptide and is administered by intravenous injection. Optionally, the composition comprises 0.1 μg/kg to 5 mg/kg Bwt of the peptide and is administered by intravitreal injection. Optionally, the composition comprises 2 to 10 mg/kg Bwt of the peptide and is administered orally.
- Optionally, the composition is administered via either intravenous (IV) or intravitreal (IVT) route at least once every 4 to 24 weeks. Optionally, the composition is administered orally at least once daily for 1 to 2 weeks at intervals of 6 months. In this treatment protocol, the composition is not administered during the 6 month interval. Optionally, for the subject not responsive to anti-VEGF therapy, for example, a VEGF antibody.
- Optionally, the subject has age-related macular degeneration, retinopathy, or vascular occlusion. Optionally, the subject has diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, or corneal neovascularization. Optionally, the subject is a human.
- Also provided herein is a method of treating a retinal angiogenic disease in a subject. The methods include selecting a subject with retinal angiogenic disease not responsive to an anti-angiogenesis therapy, and administering to the subject a composition comprising a peptide having the sequence SEQ ID NO:1, wherein administration treats the retinal angiogenic disease in the subject. Optionally, the subject is not responsive to an anti-VEGF therapy.
- Optionally, the composition disclosed herein is formulated for intravenous administration, for intravitreal injection, or for oral administration. Optionally, the subject has age-related macular degeneration, retinopathy, or vascular occlusion. Optionally, the subject has diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, or corneal neovascularization. Optionally, the subject is not responsive to anti-angiogenesis therapy. Optionally, the subject is not responsive to anti-VEGF therapy, e.g., a VEGF antibody. Optionally, the subject is a human.
- Also provided is a method of treating a retinal angiogenic disease in a subject. The method includes administering to the subject a pharmaceutically effective amount of a composition comprising a peptide N having the sequence Thr Pro His Thr His Asn Xaa Thr Pro Glu wherein Xaa is homoarginine (SEQ ID NO:3). The composition can be administered to the subject orally, by intravenous injection, or by intravitreal injection, wherein administration treats the retinal angiogenic disease in the subject.
- Also provided is a method of treating a retinal angiogenic disease in a subject. The method includes administering to the subject a pharmaceutically effective amount of a composition comprising a peptide Q having the sequence Thr Pro His Thr His Gin Xaa Thr Pro Glu wherein Xaa is homoarginine (SEQ ID NO:4), wherein the composition is administered to the subject orally, by intravenous injection, or by intravitreal injection, wherein administration treats the retinal angiogenic disease in the subject.
-
FIGS. 1A, 1B, 1C and 1D show the efficacy of a single IV dose of angio-3 in attenuating the retinal angiogenesis in KIMBA mice, which have over expression of human VEGF (KIMBA-hVEGF Transgenic).FIG. 1A is a schematic of the experimental design. -
FIG. 1B are images showing Fundus Fluorescein Angiography (FFA) images of baseline and weekly after post treatment. Digital color fundus photographs were taken using a MICRON IV comprehensive system for rodent retinal imaging (Phoenix Research Labs, Pleasanton, Calif.) after pupil dilatation with topical administration of 1% tropicamide (Alcon Laboratories, Inc., Fort Worth, Tex.) and 2.5% phenylephrine (Bausch and Lomb Pharmaceuticals, Inc., Tampa, Fla.) ophthalmic solutions. For FFA, mice were injected intraperitoneally with 10% sodium fluorescein dye at a dose of 0.01 mL/5-6 g BWt and fundus images were obtained using MICRON IV.FIG. 1C is a graph showing regression of leakage in Kimba mice by each eye and by batch. IV single injection of 100 μL of Angio-3 was given atweek 4 and followed for further 4 weeks. (25 mg/Kg Bwt). Readout is the leakage of retinal vascularization post-administration of the drug. n=6 eyes per batch; n=3 batches; Values are expressed as means±s.e.m., **P<0.01, *P<0.05, student's t-test.FIG. 1D are images showing Isolectin Retinal staining. Control and Angio-3 treated eyes were enucleated and fixed in 4% paraformaldehyde (PFA) in PBS for 15 minutes at room temperature. The eyes were then transferred to cold 1× PBS on ice for 5-10 minutes. The neural retina and choroid/RPE were dissected separately and placed in cold (−70° C.) ethanol. Retinas were then rinsed in PBS and blocked in 1% Triton-X/PBS for 30 min. The whole mounts were then incubated with Isolectin GS-IB4 from Griffonia Simplicofolia, Alexa Fluor 594 Conjugate (Molecular Probes, 121413 1:100) overnight at 4° C. Stained whole mounts were flat-mounted with Prolong Gold (Invitrogen) and left overnight. All imaging was performed with a laser-scanning confocal fluorescence microscope. -
FIGS. 2A, 2B, 2C and 2D show the efficacy of a single IVT dose of angio-3 and Eylea (anti-VEGF), positive control in attenuating the retinal angiogenesis in KIMBA mice.FIG. 2A is a schematic of the experimental design.FIG. 2B are images showing Fundus Fluorescein Angiography (FFA) images of baseline and weekly after post treatment.FIG. 2C is a graph showing regression of leakage in Kimba mice by each eye.FIG. 2D are graphs showing regression of leakage in Kimba mice by batch. IVT single injection of 1 μg in 1 μL of Angio-3 scramble; Angio-3 peptide and Eylea was given atweek 7 and followed for further 16 weeks. Readout is the leakage of retinal vascularization post-administration of the drug. n=10 eyes per batch; n=2 batches; Values are expressed as means±s.e.m., **P<0.01, *P<0.05, student's t-test. The results showed that treating with Eylea (positive control) is effective in attenuating retinal angiogenesis for 4 weeks post treatment and treating the mice with angio-3 is effective in attenuating retinal angiogenesis for 16 weeks post treatment. -
FIG. 3A is a schematic of the experimental design on the efficacy of Angio-3 in a laser-induced choroidal neovascularization (CNV) model in mice (B6J WT mice).FIG. 3B are FFA images of baseline and at different time points post treatment. IV single injection of 100 μL of Angio-3 (25 mg/Kg Bwt) was given at Day 0 (prevention mode) and 4 days after laser (regression mode) and followed for 10 weeks.FIG. 3C is a graph showing the area of leakage by each eye for various groups.FIG. 3D are graphs of the mean area of leakage of all batches for each group. Single dose of Angio-3 decreased the lesions in a laser-induced mice CNV model in both prevention and regression mode via IV route till 10 weeks and this was very significant in prevention mode. The attenuation retinal vascularization was better than scrambled peptide. n=6 eyes per batch; n=3 batches. Values are expressed as means±s.e.m., **P<0.01, *P<0.05, student's t-test.FIG. 3E is a graph of the result of the Retinal Function Test that measures ERG changes in Angio-3 treated and control. The a- and b-wave amplitude of the Angio-3 treated group, however, was similar to that of baseline values after weak 1. -
FIG. 4A is a schematic of the experimental design on the efficacy of Angio-3 by IVT administration.FIG. 4B are graphs of the area of leakage by each eye for various groups andFIG. 4C shows the mean area of leakage of all batches for each group. This figure illustrates that a single dose Angio-3 significantly reduced angiogenesis as compared to Eylea (anti-VEGF) and scrambled peptide in a laser-induced mice CNV model via IVT route. n=6 eyes per batch; n=3 batches; Values are expressed as means±s.e.m., **P<0.01, *P<0.05, student's t-test. -
FIG. 5A is a schematic of the experimental design on the efficacy of Angio-3 in a laser-induced CNV model by sub-lingual route.FIG. 5B are images showing Angio-3 significantly reduced angiogenesis than murine anti-VEGF or scrambled peptide in laser-induced mice CNV model via sub-lingual route.FIG. 5C is a graph of the mean area of leakage by groups andFIG. 5D shows the mean area of leakage of all batches for each group. n=6 eyes per batch; n=3 batches. Values are expressed as means±s.e.m., **P<0.01, *P<0.05, student's t-test. -
FIG. 6A is a schematic of the experimental design on the efficacy of Angio-3 in a laser-induced CNV model by IVT route in a prevention mode.FIG. 6B are graphs showing a single dose Angio-3 significantly reduced angiogenesis as compared to Eylea (anti-VEGF) in laser-induced rat CNV model via IVT route. n=10 rats per group; Values are expressed as means±s.e.m., n=3 independent experiment, **P<0.01, *P<0.05, student's t-test. -
FIG. 7A is a schematic of the study design on the efficacy of Angio-3 in a monkey model of laser-induced CNV.FIG. 7B are images of fundus fluorescein angiography (“FFA”) of the eye in monkeys treated with a single dose (2 mg) of Angio-3, anti-VEGF (Eylea and Lucentis) in laser induced monkey CNV model via IVT route.FIG. 7C is a graph showing regression of leakage was plotted by each eye in each group before and after treatment. n=2 monkeys per group; Values are expressed as means±s.e.m., ***P<0.001, *P<0.05, student's t-test. -
FIG. 8 is a graph showing severity of grade and percentage of grades in monkeys treated as described inFIG. 7 . Following a single IVT dose of Angio-3, Eylea and Lucentis®, the test article formulations were well tolerated and all animals appeared generally healthy. A few animals developed intraocular inflammation, mostly short-lived, in the study eye after intravitreal injection in all groups. In this intervention study, no change in lesion severity was observed for the vehicle control and the change in lesion severity was significantly different for all treatments compared with vehicle control. -
FIG. 9 is a graph showing results of laser spot area thickness and volume in monkeys before and after administration of Eylea or Angio-3. The amount of Angio-3 or Eyelea is the same as described inFIG. 7 . The laser spot area was significantly reduced after treatment as compared to pre-treatment in both groups. -
FIG. 10 are images of araldite retina sections stained with toluidine blue (Magnification 20×). The eyes were removed, postfixed for 2 to 3 days in half-strength Karnovsky fixative, and then stored in formalin until processed. Strips of tissue containing 1 or 2 lesion sites were embedded in plastic.Sections 2 μm thick were taken at 30-μm steps through the middle of each lesion. The sections were stained with toluidine blue, and the sample with the most robust lesion was designated as the central cut. This section was then evaluated by an observer (R.R.D.) masked to the treatment condition. A tissue proliferation score were calculated for each lesion based on 3 criteria: the size of the spindle cell proliferative lesion, the extent of new blood vessel proliferation in the subretinal space, and the elevation of the retina above the choriocapillaris. Vehicle treated (control) sections are thicker and more vascular compared with the drug-treated eyes. - Control sections showed more choroidal fibroplasia, increased retinal thickness, more choroidal neovascularization, multiple vessels extending once or twice the retinal thickness and retinal elevation as compared to drug-treated eyes.
-
FIG. 11 A are FFA images of baseline and at different time points post treatment. Mice received single IVT injection of Angio-3 (at a dose of 1 μg in 1 μl or 10 ng in 1 μl), and chemically modified Angio-3 peptides Pep-N (at doses of 5 μg in μl; 1 μg in μl; and 100 ng in 1 μl, respectively) and Pep-Q peptides (at doses of 5 μg in μl; 1 μg in μl; and 100 ng in 1 μl, respectively).FIG. 11 B is a graph of the area of leakage by each eye. Single dose attenuates retinal angiogenesis in laser-induced mice CNV model via IVT route till 4 weeks. All three peptides were able to significantly attenuate the choroidal angiogenesis in laser-induced CNV mouse model. Eylea is the positive control. n=18 eyes per group; Values are expressed as means±s.e.m. n=3 independent experiment, **P<0.01, *P<0.05, student's t-test. -
FIGS. 12A and 12B illustrates effect of Angio-3 on VEGF induced cell proliferation of HRMECs.FIG. 12A is a graph showing the effect of Angio-3 in combination of 10 ng/ml VEGF.FIG. 12B is a graph showing the effect of Angio-3 in combination of 50 ng/ml VEGF. -
FIGS. 13A and 13B show effect of Angio-3 on HRMEC cells migration in the presence of: 1) in EBM-2 alone, 2) EBM-2 supplemented with 50 ng/ml VEGF, 3) EBM-2 supplemented with 300 ug/ml Avastin plus 50 g/ml VEGF, 4) EBM-2 supplemented with 300 ug/ml Angio3 plus 50 g/ml VEGF, and 5) EBM-2 supplemented with 600 ug/ml Angio3 plus 50 g/ml VEGF.FIG. 13B are FFA images andFIG. 13A is a graph of the number of cells in microscopic fields under 100× objective based on the images ofFIG. 13B . -
FIGS. 14A and 14B show effect of Angio-3 on VEGF induced HRMECs tube formation in the presence of: 1) in EBM-2 alone, 2) EBM-2 supplemented with 50 ng/ml VEGF, 3) EBM-2 supplemented with 300 ug/ml Avastin plus 50 g/ml VEGF, 4) EBM-2 supplemented with 300 ug/ml Angio3 plus 50 g/ml VEGF, and 5) EBM-2 supplemented with 600 ug/ml Angio3 plus 50 g/ml VEGF.FIG. 14B are FFA images of cells.FIG. 14A is a graph of quantifications of total tube length, number of junctions, and total number of loops based on the images inFIG. 14B . **P<0.01, *P<0.05. Unless explicitly noted otherwise, the VEGF peptide disclosed in this application refers to VEGF165, a subtype of human VEGF that has the most potent biological activity and is the most abundantly present in vivo. -
FIGS. 15A and 15B are graphs showing that Angio-3 induced human umbilical vein endothelial cells (HUVECs) apoptosis in the presence of either VEGF or bFGF.FIG. 15A shows Angio-3 induced HUVEC apoptosis in the presence of 20 ng/ml VEGF in a dose-dependent manner.FIG. 15B shows that Angio-3 induced HUVEC apoptosis in the presence of 20 ng/ml bFGF in a dose-dependent manner. * represents p<0.05, n=3. -
FIGS. 16A and 16B are graphs showing Angio-3 inhibited HUVEC proliferation stimulated by VEGF and bFGF.FIG. 16A shows Angio-3 suppressed HUVEC proliferation induced by 20 ng/ml VEGF in a dose-dependent manner.FIG. 16B shows Angio-3 suppresses HUVEC proliferation induced by 20 ng/ml bFGF in a dose-dependent manner. * represents p<0.05, n=3. -
FIGS. 17A, 17B, 17C and 17D show that Angio-3 inhibited VEGF and bFGF-induced EC migration and inhibits capillary network formation.FIG. 17 A are images and 17 C is a graph showing Angio-3 suppressed HUVEC chemotactic migration induced by 20 ng/ml VEGF in a dose-dependent manner. Migrated cells were stained with Hoechst, imaged and counted.FIG. 17 B are images and 17 D is a graph showing Angio-3 suppressed HUVEC chemotactic migration that was induced by 20 ng/ml bFGF in a dose-dependent manner. Migrated cells were stained with Hoechst, imaged and counted. n=3; * represents significant reduction compared to control at P<0.05 by one-way ANOVA. -
FIGS. 18A and 18B show that Angio-3 inhibited HUVEC capillary network formation on Matrigel.FIG. 18A are representative images of HUVEC tube formation on Matrigel. HUVECs were pre-incubated with increasing doses of Angio-3 for 30 min prior to seeding on Matrigel.FIG. 18B is a graph of percentage area covered by HUVEC tubes. n=3; * represents significant reduction compared to control at P<0.05 by one-way ANOVA. -
FIGS. 19A, 19B and 19C are graphs showing that Angio-3 is a novel anti-permeability agent that can inhibit VEGF-induced vascular permeability (VP) with multiple endothelial cell types. InFIG. 19A , post-confluent HUVEC monolayers were treated with increasing concentrations of Angio-3 or medium alone. The results show that Angio-3 inhibited VEGF-induced permeability across confluent HUVECs in a dose-dependent manner without affecting the basal level permeability. In these experiments, post-confluent HUVEC monolayers were pre-treated with Angio-3 for 30 minutes prior to stimulation with 100 ng/ml VEGF. InFIG. 19B , Post-confluent HMVEC monolayers were treated with increasing concentrations of Angio-3 or medium alone. The results show that Angio-3 inhibited VEGF-induced permeability across confluent human dermal microvascular endothelial cells (HMVECs) in a dose-dependent manner without affecting the basal level permeability. InFIG. 19C , post-confluent HREC monolayers were treated with Angio-3 and VEGF for 3 h. The results show that Angio-3 inhibited VEGF-induced permeability across confluent human retinal endothelial cells (HRECs) in a dose-dependent manner without affecting the basal level permeability. * represents p<0.05, n=3. -
FIGS. 20A and 20B are images and a graph, respectively, showing that Angio-3 inhibited local VEGF-induced dermal vascular permeability in mice. InFIG. 20A , Angio-3 was administered via intradermal injection to mice and the results show that Angio-3 inhibited VEGF-induced dermal permeability in a dose-dependent manner within 15 min. The dermal permeability was visualized by Evans blue dye extravasation. InFIG. 20B , dye extravasation was quantified by formamide extraction of the dye and measuringOD 610. n=5 animals per group, * represent significantly increased as compared with the simultaneous control at p<0.05. -
FIGS. 21A, 21B, 21C and 21D are images showing Angio-3 prevented VEGF-induced dissociation of Vascular endothelial (“VE”)-cadherin from Adherens junctions (AJs) on HUVECs. Angio-3 protected VE-cadherin from VEGF-induced dissociation from cell-cell AJ. Confluent HUVEC monolayers were pre-treated with 100 μM Angio-3 for 30 min following which the monolayers were stimulated with 100 ng/ml VEGF for 20 min. Cells were then fixed, permeabilized and probed for VE-cadherin.FIGS. 21A-D shows control cells, cells treated with 100 ng/ml VEGF, cells treated with 100 uM Angio-3, and cells treated with 100 ng/ml VEGF plus 100 uM Angio-3, respectively. -
FIGS. 22A and 22B are images showing Angio-3 suppressed VEGF-induced dissociation of tight junction (TJ) proteins ZO-1 and ZO-2 from TJs in HUVECs. Cells were treated under control, 100 ng/ml VEGF, 100 μM Angio-3, and 100 ng/ml VEGF plus 100 μM Angio-3, respectively. -
FIGS. 23A, 23B, 23C and 23D are images showing Angio-3 suppressed VEGF-induced actin stress fiber formation in HUVECs. However, in the absence of VEGF, Angio-3 promoted cortical actin fiber formation. The red color represents action staining and the blue represent DAPI staining. -
FIG. 24 are graphs showing the results of retinal function tests recorded via electroretinogram (ERG). Untreated mice has no response of both a and b-waves after 12 weeks of age. Angio-3 increased the a and b-wave responses for 6 weeks post treatment and then again increased the response for 20 weeks with second dose. This result shows that Angio-3 is rescuing the retinal function in KIMBA mice. Data is represented as mean±S.D. **=P<0.05; ***=P<0.01. -
FIGS. 25A, 25B, 25C, 25D, 25E, and 25F show the results of testing in a laser-induced chorodial neovascularization (CNV) model in Cynomolgus moneys developed as an experimental model of wet AMD.FIG. 25A is a schematic of the study design.FIG. 25B are representative fundus fluorescein angiography (FFA) images of all groups.FIG. 25C is a graph showing change in mean lesion grade of the eye in monkeys treated with asingle dose 2 mg of Angio-3, dose 2 mg of anti-VEGF (Eylea), 2 mg of peptide (Q2) and 4 mg of peptide (Q4) and control.FIG. 25D is a graph of percentage of all grades pre and post treatment of Angio-3, PepQ-low dose (2 mg); PepQ-high dose (4 mg), Eylea and control eyes that was tested in laser induced choroidal neo-vascularization non-human primate model.FIG. 25E is a graph of laser area quantified from the FFA images by ImageJ software.FIG. 25F are graphs of laser volume quantified from PS-OCT images by ImageJ software. All 4 treated groups significantly reduces leakage and neovessel area as compared to vehicle control. Eylea shows the superior efficacy as compared to test peptides. However, Pep-Q shows dose dependent efficacy and higher dose efficacy is as close to Eylea. -
FIGS. 26A and 26B are images showing progression of corneal neovascularization seven days after alkali-burn injury.FIG. 26A are representative image of a vehicle treated eye.FIG. 26B are representative image of an eye treated three times per day with our compound of interest (PeptideQ). White arrow indicates the difference in corneal opacity and neovascularization. -
FIG. 27 is a graph of the area of corneal neovascularization (NV) seven days after alkali-burn injury was quantified by ImageJ software. Peptide Q treated eyes were significantly reduced corneal NV area as compared to vehicle control eyes. -
FIGS. 28A and 28B are images and a graph showing results of testing wound healing in a mouse model.FIG. 28A are representative slitlamp biomicroscopy images of murine cornea following the removal of corneal epithelium from Angio-3 treated and control wild-type mice and topical fluorescein staining of the epithelial defect (green).FIG. 28B is a graph of the percentage of wound defect remaining (vertical axis) over time (horizontal axis) in Angio-3 treated and control wild-type mice, n=6 for each group from 2 independent experiments. Both groups are statistically significant. Angio-3 didn't affect the normal wound healing process. Data is represented as mean±S.D. - Provided herein are compositions and methods for treating subjects having a retinal angiogenic disease by administering a composition comprising Angio-3 peptides. The Angio-3 peptide acts to block the formation of new vessels in patients having retinal angiogenic disease and is particularly useful for patients who are not responsive to anti-VEGF therapies. The therapy can be conveniently delivered orally or by intravenous injection, or by intravitreal injection.
- The term “about” when used in conjunction with a value means any value that is reasonably close to the value, i.e., within the range of +10% of the value. In particular, it would include the value itself. For example, both a value of 45 mg/kg and a value of 55 mg/kg are deemed to be “about 50 mg/kg”.
- The terms “subject”, “patient” or “individual” are used herein interchangeably to refer to a human or animal. For example, the animal subject may be a mammal, a primate (e.g., a monkey), a livestock animal (e.g., a horse, a cow, a sheep, a pig, or a goat), a companion animal (e.g., a dog, a cat), a laboratory test animal (e.g., a mouse, a rat, a guinea pig, a bird), an animal of veterinary significance, or an animal of economic significance.
- As used herein, the terms “not responsive,” and “non-responsive” to a treatment are used herein interchangeably to refer to a condition in which a patient or subject does not respond to a particular treatment or does not obtain a desired benefit after treatment for a particular disease. The terms “not responsive” and “non-responsive” include conditions in which a subject receives a treatment but does not experience a reduction in at least one symptom associated with the disease in the absence of the treatment. By way of example, a subject is not responsive to an anti-VEGF therapy if new blood vessels under the retinal of the patient continue to form despite receiving an anti-VEGF therapy or if a new blood vessel continues to grow while receiving the treatment.
- As used herein, the term “non-responder” refers to a subject that is administered a therapeutic treatment for a particular disease but does not respond to or obtain benefit from the therapy. The term refers to subjects that do not experience a reduction in at least one symptom associates with the disease, e.g., a retinal angiogenic disease.
- As used herein, “treating” or “treatment of” a condition, disease or disorder or symptoms associated with a condition, disease or disorder refers to an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of condition, disorder or disease, stabilisation of the state of condition, disorder or disease, prevention of development of condition, disorder or disease, prevention of spread of condition, disorder or disease, delay or slowing of condition, disorder or disease progression, delay or slowing of condition, disorder or disease onset, amelioration or palliation of the condition, disorder or disease state, and remission, whether partial or total. “Treating” can also mean prolonging survival of a subject beyond that expected in the absence of treatment. “Treating” can also mean inhibiting the progression of the condition, disorder or disease, slowing the progression of the condition, disorder or disease temporarily, although in some instances, it involves halting the progression of the condition, disorder or disease permanently. As used herein the terms treatment, treat, or treating refers to a method of reducing the effects of one or more symptoms of a disease or condition characterized by expression of the protease or symptom of the disease or condition characterized by expression of the protease. Thus in the disclosed method, treatment can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease, condition, or symptom of the disease or condition. For example, a method for treating a disease is considered to be a treatment if there is a 10% reduction in one or more symptoms of the disease in a subject as compared to a control. Thus the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to native or control levels. It is understood that treatment does not necessarily refer to a cure or complete ablation of the disease, condition, or symptoms of the disease or condition. Further, as used herein, references to decreasing, reducing, or inhibiting include a change of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater as compared to a control level and such terms can include but do not necessarily include complete elimination.
- The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to include a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. As used herein, the terms encompass amino acid chains of any length, including full-length proteins (i.e., antigens), wherein the amino acid residues are linked by covalent peptide bonds.
- The term “amino acid” includes naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs include compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. “Amino acid mimetics” include chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
- Amino acids may be referred to herein by either the commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
- As to amino acid sequences, one of skill will recognize that individual substitutions, deletions and/or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and/or alleles.
- The following eight groups each contain amino acids that are conservative substitutions for one another:
- 2) Aspartic acid (D), Glutamic acid (E);
- (see, e.g., Creighton, Proteins (1984)).
- The term “therapeutically effective amount” or “effective mount” includes an amount or quantity effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
- The term “administering” includes oral administration, topical contact, administration as a suppository, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal, or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. One skilled in the art will know of additional methods for administering a therapeutically effective amount of a fusion protein described herein.
- Described herein are methods to treat subjects suffering from a number of retinal angiogenic diseases, e.g., age-related macular degeneration, retinopathy, or vascular occlusion. Retinopathy refers to a disease of the retina that results in impairment or loss of vision. Age-related macular degeneration (“AMD”) is characterized by the invasion of new blood vessels into different-structures of the eye such as macular and retinal pigment epithelium. Vascular occlusion is a blockage in the retinal blood vessels, arteries or veins. Optionally, the subject has diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, or corneal neovascularization. Subjects having one of these conditions may experience one or more of the following symptoms, visual field defects, difficulty to see textures and subtle changes in the environment, and difficulty to adjust for changing light levels, and impaired depth perception. Retinal angiogenic diseases can be diagnosed by a trained optometrist or other medical professional using methods well known in the art to examine the blood vessel formation under the retina, such as Dilated Eye Exam, Autofluorescence, Fundus Photography, Fluorescein Angiography, Optical Coherence Tomography (OCT), Tonometry, Fundoscopy or Ophthalmoscopy
- Optionally, the subject treated with the Angio-3 peptide was previously determined to be non-responsive to anti-angiogenesis therapies, e.g., anti-VEGF therapies. As used herein, anti-angiogenesis therapy refers to a therapy that blocks angiogenesis. As used herein, an anti-VEGF therapy refers to a therapy that blocks one or more VEGF function. Non-limiting examples of anti-angiogenesis therapies include pegaptanib (Macugen™. by Pfizer), ranibizumab (Lucentis™ by Genentech) bevacizumab (Avastin™ by Genentech), carboxyamidotriazole, TNP-470, CM101, IFN-α, IL-12,
platelet factor 4, suramin, SU5416, thrombospondin, VEGFR antagonists, angiostatic steroids+heparin, cartilage-derived angiogenesis inhibitory factor, matrix metallopreteinase inhibitors, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, prolactin, alphaV.beta3 inhibitors, linomide, VEGF-Trap (by Regeneron Pharmaceuticals), Aminosterols (Evizion® by Genera Corp.), Cortisen (Retaane® by Alcon), tyrosine kinase inhibitors, anti-angiogenic siRNA, inhibitors of the complement system, gentherapeutic therapies (e.g. AdPEDF.11 by Genvec (Gaithersburg, Md.). Optionally, the anti-VEGF therapy is an anti-VEGF antibody, for example bevacizumab that are commercially available. - Optionally, the method of treating a retinal angiogenic disease comprises selecting a subject that has been diagnosed with a retinal angiogenic disease but is not responsive to anti-VEGF therapy. Administering the composition comprises an Angio-3 peptide disclosed herein, e.g., any one of SEQ ID Nos 1-4, or any combination thereof.
- Angiostatin is a fragment of plasmin, which is a fragment of plasminogen. Plasminogen (UniProt No. P00747) contains five homologous repeats that form looped “kringle” structures held together by disulfide bonds. Plasminogen binds to fibrin through lysine binding sites located on the five kringle domains (k1 through k5) (Folkman et al, Nature Medicine, vol. 1, No. 1, pp. 27-31 1999). Each kringle domain is about 80 amino acid residues in length and different kringle domains are highly homologous to each other in amino acid sequences. Angio-3, is derived from the kringle domain k4 of plasminogen and is an angiogenesis inhibitor, i.e., it blocks the growth of new blood vessels, and has anti-inflammatory/anti-angiogenic activity. Angio-3 signaling pathway mediates the switch between a quiescent and an activated (i.e., angiogenic) endothelium. Unlike Vascular Endothelial Growth Factor (VEGF), which appears to uniformly promote angiogenesis, Angio-3 appears to have differing functions depending on endothelial cell context, with both cell-to-cell and cell-to-matrix contacts modulating the resulting signals.
- It is believed that in many cases, patients having retinal angiogenic disease are not responsive to VEGF inhibitor therapy or become non-responsive after a period of time of treatment resulting in protection of VEGF-dependent endothelium. As described herein, delivering Angio-3 can disrupt the formation of new vessels and patients may be able to overcome resistance to anti-VEGF therapies. In particular, administering Angio-3 peptides can attenuate the retinal and/or choroidal angiogenesis and/or reduce lesion area of leakage in the eye caused by retinal angiogenesis.
- The Angio-3 peptide that can be used to treat a retinal angiogenic disease can be the native Angio-3 peptide, which has a sequence of Thr Pro His Thr His Asn Arg Thr Pro Glu (SEQ ID NO: 1). The Angio-3 peptide can also be a peptide that contains modifications from SEQ ID NO:1 and yet retains the function of blocking angiogenesis. Some exemplar modifications to the peptide include sequence modifications and chemical modifications.
- The polynucleotide sequences may encode Angio-3 polypeptides including those sequences with deletions, insertions, or substitutions of different nucleotides, which result in a polynucleotide encoding a polypeptide with at least one functional characteristic of the instant polypeptides, as described herein. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding the instant polypeptides, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding the instant polypeptides.
- Sequence alterations that do not change the amino acid sequence encoded by the polynucleotide are termed “silent” variations. Due to the degeneracy of the genetic code, with the exception of the codons ATG and TGG, encoding methionine and tryptophan, respectively, any of the possible codons for the same amino acid can be substituted by a variety of techniques, for example, site-directed mutagenesis, available in the art. Accordingly, any and all such variations of a sequence selected from the Sequence Listing are a feature of the instant disclosure.
- In addition to silent variations, other conservative variations that alter one or a few amino acid residues in the Angio-3 peptide, can be made without altering the function of the polypeptide. For example, substitutions, deletions and insertions introduced into the sequences provided herein are also envisioned. Amino acid substitutions are typically of single residues; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. In preferred embodiments, deletions or insertions are made in adjacent pairs, for example, a deletion of two residues or insertion of two residues. Substitutions, deletions, insertions or any combination thereof can be combined to arrive at a sequence. The mutations that are made in the polynucleotide encoding the peptide should not place the sequence out of the reading frame and should not create complementary regions that could produce secondary mRNA structure. Preferably, the polypeptide encoded by the DNA performs the desired function.
- Conservative substitutions are those in which at least one residue in the amino acid sequence has been removed and a different residue inserted in its place. Such substitutions generally are made when it is desired to maintain the activity of the protein. Although all conservative amino acid substitutions (e.g., one basic amino acid substituted for another basic amino acid) in a polypeptide will not necessarily result in the polypeptide retaining the same activity as the native polypeptide, it is expected that many of these conservative mutations would result in the polypeptide retaining its activity.
- Sequence variants of the Angio-3 peptides can be produced by modifying the respective wild-type sequences according to methods well-known to the skilled in the art. Such methods include, but not limited to, mutagenesis by PCR, which uses primers designed to contain desired changes; nested primers to mutate a target region; and inverse PCR, which amplifies a region of unknown sequence using primers orientated in the reverse direction. Many other mutation and evolution methods are also available and expected to be within the skill of a person of ordinary skill in the relevant art. Sequence variants of the Angio-3 peptide (SEQ ID NO: 1), as well as the Angio-3 peptide itself, can also be synthesized in the laboratory using methods well known in the art for peptide synthesis.
- Accordingly, the disclosure also provides a scrambled Angio-3 peptide that has a sequence of Asn Thr Thr Glu Thr Pro His Pro His Arg (SEQ ID NO:2), which is used as a negative control for some of the studies disclosed herein.
- Chemical or enzymatic alterations of expressed nucleic acids and polypeptides can be performed by standard methods. For example, sequences can be modified by the addition of lipids, sugars, peptides, organic or inorganic compounds, by the inclusion of modified nucleotides or amino acids, or the like. These methods can be used to modify any given sequence, or to modify any sequence produced by the various mutation and artificial evolution modification methods described herein and known to those of skill in the art.
- The Angio-3 peptides disclosed herein may include natural amino acids, and, optionally, post-translational modifications thereof. However, in vitro peptide synthesis permits the use of modified and/or non-natural amino acids. A table of exemplary, but not limiting, modified and/or non-natural amino acids is provided herein below.
-
TABLE 1 Modified Amino Acids Abbr. Amino Acid Abbr. Amino Acid Aad 2-Aminoadipic acid EtAsn N-Ethylasparagine BAad 3-Aminoadipic acid Hyl Hydroxylsine BAla beta-alanine, beta-Amino-propionic AHyl allo-Hydroxylysine acid Abu 2-Aminobutyric acid 3Hyp 3-Hydroxyproline 4Abu 4-Aminobutyric acid, piperidinic 4Hyp 4-Hydroxyproline acid Acp 6-Aminocaproic acid Ide Isodesmosine Ahe 2-Aminoheptanoic acid Aile allo-Isoleucine Aib 2-Aminoisobutyric acid MeGly N-Methylglycine, sarcosine BAib 3-Aminoisobutyric acid Melle N-Methylisoleucine Apm 2-Aminopimelic acid MeLys 6-N- Methylly Dbu 2,4-Diaminobutyric acid MeVal N-Methylvaline Des Desmosine Nva Norvaline Dpm 2,2′-Diaminopimelic acid Nle Norleucine Dpr 2,3-Diaminopropionic acid Orn Ornithine EtGly N-Ethylglycine - Accordingly, the present disclosure provides for modifications of any given nucleic acid by mutation, chemical or enzymatic modification, or other available methods, as well as for the products produced by practicing such methods, e.g., using the sequences herein as a starting substrate for the various modification approaches.
- Optionally, the modification to the native Angio-3 is to substitute arginine with a homoarginine. Homoarginine is the methylene homologue of L-arginine (Arg). It is an amino acid derivative and may increase nitric oxide availability and enhance endothelial function. Thus, optionally, the Angio-3 peptide that can be used to treat the retinal angiogenic diseases is Pep-N, which has a sequence of Thr Pro His Thr His Asn Xaa Thr Pro Glu, wherein Xaa is homoarginine (SEQ ID NO:3). Optionally, the Angio-3 peptide that can be used to treat the retinal angiogenic disease is Pep-Q, which has a sequence of Thr Pro His Thr His Gin Xaa Thr Pro Glu, wherein Xaa is homoarginine (SEQ ID NO:4).
- The Angio-3 peptide may be prepared by methods known in the art. These methods include synthetic peptide chemistry, recombinant expression of the peptides of the disclosure using appropriate prokaryotic or eukaryotic host cells and expression systems or recombinant expression of the peptide as a feature of somatic gene transfer, i.e., expression as part of the administration regimen at the site of treatment.
- Optionally, the peptide can be synthesized chemically using standard peptide synthesis techniques, e.g., solid-phase or solution-phase peptide synthesis. That is, the peptides disclosed as SEQ ID NOs:1-4 may be chemically synthesized, for example, on a solid support or in solution using compositions and methods well known in the art, see, e.g., Fields, G. B. (1997) Solid-Phase Peptide Synthesis. Academic Press, San Diego, incorporated by reference in its entirety herein. Such standard peptide-preparation techniques include, for example, solution synthesis or Merrifield-type solid phase synthesis, Boc (tert.butyloxycarbonyl), and the Fmoc (9-fluorenylmethyloxycarbonyl) strategies. Optionally, the peptides are synthesized by solid phase Fmoc chemistry using methods well known in the art (Ajikumar P K, Lakshminarayanan R, Ong B T, Valiyaveettil S, Kini R M. Biomacromolecules. 2003 September-October; 4(5):1321-6).
- Provided herein is a pharmaceutical composition including a pharmaceutically acceptable excipient and an Angio-3 peptide. Also provided is a method of administering the composition for treating retinal angiogenic diseases, especially for subjects who are not responsive to anti-angiogenesis therapies, e.g. anti-VEGF therapies.
- Pharmaceutical compositions or medicaments can be formulated by standard techniques using one or more physiologically acceptable carriers or excipients. Suitable pharmaceutical carriers are described herein and in, e.g., “Remington: The Science and Practice of Pharmacy, Twenty-First Edition” by E. W. Martin. The Angio-3 peptides and their physiologically acceptable salts and solvates can be formulated for administration by any suitable route, including, but not limited to, orally, topically, nasally, rectally, parenterally (e.g., intravenously, subcutaneously, intramuscularly, etc.), and combinations thereof. Optionally, the therapeutic agent is dissolved in a liquid, for example, water.
- For oral administration, a pharmaceutical composition or a medicament disclosed herein can take the form of, e.g., a tablet or a capsule prepared by conventional means with a pharmaceutically acceptable excipient. Preferred are tablets and gelatin capsules comprising the active ingredient(s), together with (a) diluents or fillers, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose (e.g., ethyl cellulose, microcrystalline cellulose), glycine, pectin, polyacrylates and/or calcium hydrogen phosphate, calcium sulfate, (b) lubricants, e.g., silica, anhydrous colloidal silica, talcum, stearic acid, its magnesium or calcium salt (e.g., magnesium stearate or calcium stearate), metallic stearates, colloidal silicon dioxide, hydrogenated vegetable oil, corn starch, sodium benzoate, sodium acetate and/or polyethyleneglycol; for tablets also (c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone and/or hydroxypropyl methylcellulose; if desired (d) disintegrants, e.g., starches (e.g., potato starch or sodium starch), glycolate, agar, alginic acid or its sodium salt, or effervescent mixtures; (e) wetting agents, e.g., sodium lauryl sulfate, and/or (f) absorbents, colorants, flavors and sweeteners. Optionally, the tablet contains a mixture of hydroxypropyl methylcellulose,
polyethyleneglycol 6000 and titatium dioxide. Tablets may be either film coated or enteric coated according to methods known in the art. - Liquid preparations for oral administration can take the form of, for example, solutions, syrups, or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives, for example, suspending agents, for example, sorbitol syrup, cellulose derivatives, or hydrogenated edible fats; emulsifying agents, for example, lecithin or acacia; non-aqueous vehicles, for example, almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils; and preservatives, for example, methyl or propyl-p-hydroxybenzoates or sorbic acid. The preparations can also contain buffer salts, flavoring, coloring, and/or sweetening agents as appropriate. If desired, preparations for oral administration can be suitably formulated to give controlled release of the active compound.
- For topical administration, the compositions of the present disclosure can be in the form of emulsions, lotions, gels, creams, jellies, solutions, suspensions, ointments, and transdermal patches. For delivery by inhalation, the composition can be delivered as a dry powder or in liquid form via a nebulizer. For parenteral administration, the compositions can be in the form of sterile injectable solutions and sterile packaged powders. Preferably, injectable solutions are formulated at a pH of about 4.5 to about 7.5.
- The compositions can also be provided in a lyophilized form. Such compositions may include a buffer, e.g., bicarbonate, for reconstitution prior to administration, or the buffer may be included in the lyophilized composition for reconstitution with, e.g., water. The lyophilized composition may further comprise a suitable vasoconstrictor, e.g., epinephrine. The lyophilized composition can be provided in a syringe, optionally packaged in combination with the buffer for reconstitution, such that the reconstituted composition can be immediately administered to a patient.
- The compounds can be encapsulated in a controlled drug-delivery system such as a pressure controlled delivery capsule, a colon targeted delivery system, a osmotic controlled drug delivery system, and the like. The pressure controlled delivery capsule can contain an ethylcellulose membrane. The colon target delivery system can contain a tablet core containing lactulose which is over coated with an acid soluble material, e.g., Eudragit E®, and then overcoated with an enteric material, e.g., Eudragit L®. The osmotic controlled drug delivery system can be a single or more osmotic unit encapsulated with a hard gelatin capsule (e.g., capsule osmotic pump; commercially available from, e.g., Alzet, Cupertino, Calif.). Typically, the osmotic unit contains an osmotic push layer and a drug layer, both surrounded by a semipermeable membrane.
- Pharmaceutical compositions or medicaments can be administered to a subject at a therapeutically effective dose to treat a retinal angiogenic disease as described herein. Optionally, the pharmaceutical composition or medicament is administered to a subject in an amount sufficient to elicit an effective therapeutic response in the subject.
- Typically, a dosage of the active compounds is a dosage that is sufficient to achieve the desired effect. Optimal dosing schedules can be calculated from measurements of agent accumulation in the body of a subject. Generally, administered dosages can vary depending on a number of factors, including, but not limited to, the subject's body weight, age, individual condition, surface area or volume of the area to be contacted, and/or on the routes of administration. The size of the dose will also be determined by the existence, nature, and extent of any adverse effects that accompany the administration of a particular compound in a particular subject. Preferably, the smallest dose and concentration required to produce the desired result should be used. Dosage should be appropriately adjusted for children, the elderly, debilitated patients, and patients with cardiac and/or liver disease. Further guidance can be obtained from studies known in the art using experimental animal models for evaluating dosage.
- Optionally, the composition is administered by intravenous injection. A unit dosage for intravenous administration to an individual (e.g., human) may contain 2-50 mg of active ingredient per 1 kg of body weight, which is also referred to as 2-50 mg/kg Bwt. For example, for a patient of about 50 kg, the unit dosage may contain 100 mg-2,500 mg of the active ingredient of Angio-3 peptide. Optionally, the unit dosage is 2-50 mg/kg Bwt., e.g., 10-50 mg/kg Bwt., 25-45 mg/kg Bwt., or 20 to 40 mg/kg Bwt. The volume of the unit dosage varies, Optionally, the volume is within a range of 10-200 μl, e.g., 40-150 μl, 100-200 μl, 120-150 μl, or 50-160 μl.
- Optionally, the composition is administered by intravitreal injection. Typically, a unit dosage for intravitreal administration may contain 0.1 μg/kg Bwt.-2 mg/kg Bwt., e.g., 0.5 μg/kg Bwt.-2 mg/kg Bwt., 1-2 mg/kg Bwt., or 1 to 1.5 mg/kg of the angio-3 peptide. The volume of the unit dosage may vary, for example, it may be a volume within the range of 10-80 μl, e.g., 20-60 μl, or 30-50 μl.
- Optionally, the composition is administered orally. Typically, a unit dosage for oral administration may contain 2 mg/kg Bwt.-10 mg/kg Bwt., e.g., 2 μg/kg Bwt.-8 mg/kg Bwt., 5-10 mg/kg Bwt., or 4 to 6 mg/kg of the Angio-3 peptide.
- The dosage of a composition can be monitored and adjusted throughout administration period, depending on severity of symptoms, frequency of recurrence, and/or the physiological response to the therapeutic regimen. Those of skill in the art commonly engage in such adjustments in therapeutic regimens.
- To achieve the desired therapeutic effect, the compositions may be administered for multiple days at the therapeutically effective dose. Thus, therapeutically effective administration of the compositions of the disclosure to treat a pertinent condition or disease described herein in a subject requires periodic (e.g., daily) administration that continues for a period ranging from four weeks or two years or longer. A therapeutically beneficial effect can be achieved if the agents are administered daily, or at a frequency that is enough to maintain a therapeutically effective concentration of the agents in the subject. For example, one can administer the agents every day, every other day, or, if higher dose ranges are employed and tolerated by the subject, e.g., twice a week.
- The duration of treatment with Angio-3 peptides to treat patients vary according to severity of the condition in a subject and the subject's response to Angio-3. Treatment with the Angio-3 in accordance with the disclosure thus may last for as long as five, six, eight, ten weeks or even longer. Optionally, the composition can be administered for a period of about 4 weeks to 2 years, more typically about 6 weeks to about 1 year, most typically about 6 months to 1 year. Suitable periods of administration also include about 18 weeks to 1 year, 9 to 16 weeks, 16 to 24 weeks, 16 to 32 weeks, 24 to 32 weeks, 24 to 48 weeks, 32 to 48 weeks, 32 to 52 weeks, 48 to 52 weeks, 48 to 64 weeks, 52 to 64 weeks, 52 to 72 weeks, 64 to 72 weeks, 64 to 80 weeks, 72 to 80 weeks, 72 to 88 weeks, 80 to 88 weeks, 80 to 96 weeks, 88 to 96 weeks, and 96 to 104 weeks. Suitable periods of administration also include 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 25, 30, 32, 35, 40, 45, 48, and 50 weeks. Generally administration of the composition should be continued until clinically significant improvement of the condition is observed.
- Optionally, administration of the composition comprising the Angio-3 peptide is not continuous and can be stopped for one or more periods of time, followed by one or more periods of time where administration resumes. Suitable periods where administration stops include 1 to 9 months, 1 to 6 months, 9 to 16 weeks, 16 to 24 weeks, 2 to 32 weeks, 24 to 32 weeks, 24 to 48 weeks, 32 to 48 days, 32 to 52 days, 48 to 52 days, 48 to 64 days, 52 to 64 days, 52 to 72 days, 64 to 72 days, 64 to 80 days, 72 to 80 days, 72 to 88 days, 80 to 88 days, 80 to 96 days, 88 to 96 days, and 96 to 100 days. Suitable periods where administration stops also include 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 25, 30, 32, 35, 40, 45, 48 50, 52, 55, 60, 64, 65, 68, 70, 72, 75, 80, 85, 88 90, 95, 96, and 100 days.
- Optionally, the composition is administered orally to patients once, twice, or more times per day. Optionally, the daily oral administration of the composition comprising the Angio-3 peptide is administered for at least two (2) weeks, at least three (3) weeks, or for 1-2 weeks during a time interval. In some cases, the interval is 3, 4, 6, 7, or 8 months. In general, administration of Angio-3 is continued until the desired therapeutic benefit is achieved. The entire treatment period, from the delivering the first dose to the delivery of the last dose, may be 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 25, 30, 32 months. Optionally, the entire treatment period lasts 6 to 10 months, 12 to 24 months, 6 to 32 weeks, 24 to 32 weeks, 24 to 48 weeks, 32 to 48 months, or 32 to 52 months.
- Optionally, the composition is delivered either intravenously or intravitreally at least once, twice, or more every 24 weeks, every 20 weeks, every 15 weeks, every 12 weeks, every 10 weeks, or every 4 weeks. Optionally, the composition is delivered either intravenously or intravitreally once every 4 to 10 weeks.
- The Angio-3 composition disclosed herein can be used in combination with other active agents known to be useful for treating a retinal angiogenic disease, or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of atropine. The Angio-3 composition can also be used in conjunction with laser therapy or surgery to treat a retinal angiogenic disease.
- An Angio-3 composition disclosed herein can be placed in an appropriate container, such as bottles or droppers, and labeled for treatment of an indicated condition. For administration of the atropine composition, such labeling would include, e.g., instructions concerning the amount, frequency and method of administration.
- Patients are monitored by eye examinations at the beginning of the treatment and during periodic examinations during and/or after treatment. In some cases, the patients are monitored, e.g., every four, five, six months, seven, or eight months during and/or after the treatment period. Methods for determining the progression of retinal angiogenic disease are well known, for example through Colour Fundus photography (“CFP”), Fundus Fluorescein Angiography (“FFA”), Optical coherence tomography (“OCT”) an visual acuity test. The response to treatment is assessed by both qualitative and quantitative analysis via clinical scoring system.
- The following examples are for illustrative purposes only and should not be interpreted as limitations. There are a variety of alternative techniques and procedures available to those of skill in the art, which would similarly permit one to successfully perform the provided methods.
- This Pilot efficacy study was conducted on NHP laser induced choroidal neovascularization (“CNV”) model. Four monkeys were used for this pilot study and each animal was undergone eye examination procedures. Animals were sedated with ketamine intramuscularly (10-20 mg/kg) and Medetomidine (0.02 mg/kg; IM). Topical anaesthesia (1-2 drops of 1% xylocaine) was applied to reduce the discomfort of the eyes. Pupils of non-human primates were dilated with 2.5% phenylephrine hydrochloride and 1% tropicamide drops for the ocular imaging procedures.
- Laser photocoagulation was performed on both eyes of the animals to create a model for CNV as previously described (Lai C M et al., 2005). Briefly, nine laser burns was delivered around the macula of each eye in the manner of a grid with a protocol of 500-800 mW power intensity, 50-micron spot size, and 0.1-s duration. The distance from each laser spot to the central fovea was maintained at 0.5 to 1 disc diameter size. Care was taken to avoid damaging the fovea.
- Animals was observed twice daily for signs of potential adverse events, and once daily for qualitative assessment of food consumption. The body weights of the animals were recorded on the day of transfer, at the time of animal selection for laser injury and on the day of dose administration, and every week throughout the remainder of the study.
- After the animal being anesthetized, the eyes were locally anesthetized by putting a drop of xylocaine in the conjunctival sac. A 5% povidone iodine solution was placed in the conjunctival sac. A self-retaining eyelid speculum was placed in the eye. Caliper was used to measure and mark a location at 2 mm behind the limbus. Forceps was also be used to stabilize the eye and the intravitreal injection was performed using a 30-gauge needle. The tested compounds (2 mg in 50 μl) were administered single IVT injection into both eyes on day 15 (14 days after laser injury). Daily cage-side observations were performed on all animals to monitor for clinical signs of poor health, including any ocular abnormalities.
- Fundus photography was carried out on both eyes at pre-laser and
day 14 post-laser andday 29 post laser (2 weeks after treatment). For photography the pupils were dilated as mentioned above and imaged with a fundus camera (TopCon Corp., Tokyo, Japan). The fundus photographs were used to detect any changes in the retina such as inflammation and pigmentation. - FFA was performed on both eyes by intravenous injection of 10% sodium fluorescein dye (0.1 ml/kg body wt). The fundus images were taken between 10 s and 15 min after dye injection. FFA images were assessed and graded according to standardized system:
-
-
Grade 1—No hyperfluorescence—No leak -
Grade 2—Hyperfluorescence—No leak -
Grade 3—Hyperfluorescence—Late leak -
Grade 4—Bright Hyperfluorescence with Late Leak Beyond Spot
-
- OCT was carried out on both eyes at pre-laser and
day 14 post-laser andday 29 post laser (2 weeks after treatment). - Animals were sacrificed on
Day 30. Eye, blood, ocular fluids and internal organs were collected for further analysis. - Animals were sacrificed on the proposed day (day 30) and the upper body was perfused through the aorta (descending clamped) with half-strength Karnovsky fixative. The eyes were removed, postfixes for 2 to 3 days in half-strength Karnovsky fixative, and then stored in formalin until processed. Strips of tissue containing 1 or 2 lesion sites were embedded in plastic.
Sections 2 μm thick were taken at 30-μm steps through the middle of each lesion. The sections were stained with toluidine blue, and the sample with the most robust lesion was designated as the central cut. This section was then evaluated by an observer masked to the treatment condition. - A tissue proliferation score was calculated for each lesion based on 3 criteria: the size of the spindle cell proliferative lesion, the extent of new blood vessel proliferation in the subretinal space, and the elevation of the retina above the choriocapillaris. Each measure was graded from 0 to 3, with 0 indicating not present. The total tissue proliferation score comprises the sum of each of the described measures for each laser lesion site.
- Our study result showed that Angio-3 peptide significantly attenuates the retinal angiogenesis in KIMBA mice (
FIG. 1A-D ). Eylea (positive control) is only effective for 4 weeks post treatment when commenced treatment at 6 weeks of old Kimba mice via IVT. However, Angio-3 (test peptide) is effective for up to 16 weeks post treatment (FIG. 2A-D ). This data indicates the long duration of Angio-3 efficacy in mice model Laser-induced mice model study demonstrated that Angio-3 peptide significantly attenuates the retinal and choroidal angiogenesis via IN route by single dose till week 10 (FIGS. 3A-C ). The systemic route did not affect the natural wound healing process, menstrual cycle and behavioural change, which shows that Angio-3 is safe to given via IV route. Angio-3 also significantly attenuates the retinal and choroidal angiogenesis than anti-VEGF via IVT route (FIGS. 4A-B ). Angio-3 also shows significantly attenuates the retinal and choroidal angiog than anti-VEGF via sub-lingual route (FIG. 5A-C ). In addition, our study shows that Angio-3 could be a potential long acting anti-angiogenic for retinal and choroidal angiogenesis diseases (FIGS. 3 and 4 ). In addition, we also determine the retinal function with and without Angio-3 treatment. There was no significant difference in retinal function noticed in all groups. However, a and b-wave response was lower than baseline at week 26 that was due to normal ageing process (FIG. 3D ). The optimal dose was found in rat CNV model study. Angio-3 significantly attenuates the retinal and choroidal angiogenesis than anti-VEGF via IVT route at 5 μg dose (FIGS. 6A-B ). - This NHP pilot study shows that 2 mg in 50 μl dose of SIPRAD-0276 (Angio-3) was well tolerated via IVT and no signs of inflammation found. This dose showed that same efficacy as compared to 2 mg in 50 μl of Eylea (
FIGS. 7A-C ). However, this was not superior to Lucentis. Severity of lesion grade was significantly reduced as compared to vehicle control (FIG. 8 ). Lesion area of volume and thickness was significantly reduced post treatment (FIG. 9 ). - Based on histopathological analysis (
FIG. 10 ), vehicle treated (control) sections are thicker and more vascular compared with the drug-treated eyes. Control sections showed more choroidal fibroplasia (red arrows), increased retinal thickness, more choroidal neovascularization (white arrows), multiple vessels extending once or twice the retinal thickness and retinal elevation as compared to drug-treated eyes. In this figure, the degree of vessel leakiness was associated with morphological changes in the retina at the site of laser injury. A distorted retinal architecture was apparent if a laser spot was strongly leaky at theday 29 time point, as revealed by thickening of the retina, massive fibrosis, and edematous vacuoles. Control sections are thicker and more vascular compared with the drug-treated eyes. - Angio-3 peptide also suppresses VEGF-induced endothelial cell vascular permeability (VP) in vitro including VEGF-induced VP of human retinal endothelial cells (HRECs). It also inhibits dermal vascular permeability in mice. It is envisioned that Angio-3 would also inhibit VP in the eye and this function contribute to Angio-3's function to suppress vascular leakage in the Kimba mice eye.
- Laser-induced CNV in NHP is the gold-standard for drug discovery and development of RAD. This pilot study result confirms that Angio-3 shows efficacy as close to Eylea and this peptide would be benefit to anti-angiogenesis therapy non-responders.
- This peptide can be administered as intravenous or oral or via IVT application for prevention or treatment of retinal angiogenic diseases.
- The animal model study result confirms that Angio-3 has a long-term anti-VEGF effect, therefore has potentially greater benefit than current drug on the market.
- As compared to current drugs for the same disease condition, we can produce even higher concentration (will find out tolerable highest dose from next study) for low cost as this peptide has only 10 amino acid residues.
- Aim of this study was to evaluate the efficacy of Angio-3 peptide against comparator murine anti-VEGF on retinal angiogenic diseases. C57BL/6J wild type (WT) mice were purchased from InVivos (Singapore). Kimba transgenic mice breeders were purchased from The Lions Eye Institute, Perth, Australia. Brown Norway rats were purchased from Charles & River Laboratories. In our facility, KIMBA mice breeding colony was maintained and mice were bred for the present study. Animals were housed on a 12 h light/12 h dark cycle with food and water provided ad libitum. Handling and care of all animals were performed according to the guidelines approved by SingHealth Institutional Animal Care and Use Committee (IACUC], Singapore, and is conducted in accordance with the Association for Research in Vision and Ophthalmology (ARVO) recommendations for animal experimentation.
- The Kimba mouse (n=39) is a transgenic mouse model for retinal neovascularisation, generated through photoreceptor-specific over expression of human vascular endothelial growth factor (hVEGF) protein. The retinal neovascular changes include increased permeability, pericyte and endothelial cell loss, vessel tortuosity, leukostasis and capillary blockage, dropout and haemorrhage. The Kimba mouse model is particularly suitable for testing anti-angiogeneic molecules designed to target hVEGF.
- Laser induced choridal neo-vascularization (CNV) in C57/BL6J (B6J) wild type mice (n=90).
- Laser induced choridal neo-vascularization (CNV) in Brown-Norway rats (n=30).
- Kimba mice received 25 mg/kg Bwt Angio-3 via intravenous (IV) route, single injection of 100 μl volume.
- Angio-3 was also injected via intravitreal (IVT) route in Kimba mice, single injection of 1 μl volume at 1 μg dose.
- In B6J mice, single injection of 100 μl volume at 25 mg/kg Bwt concentration Angio-3 was injected via intravenous (i/v) route and this was tested in both Preventive mode (before laser) and Regression mode (4 days after laser).
- In B6J mice, 10 μl volume at 3 mg/kg Bwt concentration Angio-3; 10 μl volume at 3 mg/kg Bwt concentration Angio-3 scramble and 10 ul volume at 0.1 mg/kg Bwt concentration anti-VEGF was given via sub-lingual (oral) route and this was tested in Regression mode (4 days after laser) and continued for 5 days (single dose per day).
- Angio-3 was also injected via intravitreal (IVT) route, single injection of 1 μl volume at 2 different doses; 1 μg (High dose) and 100 ng (Low dose).
- This was further evaluated in Brown-Norway rats to identify the optimal dose of Angio-3. Rats received 5 μg (High dose) and 1 μg (Low dose) of Angio-3 via IVT route, single injection of 3 μl volume.
- 4 laser photocoagulation sites were placed concentrically around the optic disc of both eyes to induce CNVs. A diode laser (810 nm) was used with a relative potency scale of 120 mW for mice and 250 mW for rats, an exposure time of 0.05 s, and a spot size of 50 μm. Laser spots were focused with crystal covers to avoid laser beam dispersion. Bubble formation was confirmed the rupture of Bruch's membrane.
- Fundus photography and fundus fluorescein angiography (FFA) was imaged using a MICRON IV fundus camera (Phoenix Laboratories USA). For FFA, animals were intraperitoneally injected with 10% sodium fluorescein at a dose of 0.01 ml per 5-6 μm body weight.
- The whole procedure took about 10-15 min per animal. At end post treatment day 28 (Kimba and IVT mice; rat group) and week 25 (IV mice group)], animals were euthanized by overdose of pentobarbital for blood and tissue collection.
- Animals were dark-adapted overnight (12 h), and the preparations for recordings were carried out under dim red light. Anesthesia and pupil dilation were induced as described. Animals were lightly secured to a stage with fastener strips across the upper and lower back to ensure a stable, reproducible position for ERG recordings. Body temperature was maintained between 37° C. and 38° C. with a pumped water heating pad (TP500 T/Pump; Gaymar Industries, Orchard Park, N.Y.) fixed to the top of the stage. ERGs were recorded (Espion; Diagnosis LLC, Redwood City, Calif.) with corneal monopolar electrodes (Mayo, Aichi, Japan). A gold-cup electrode (Grass-Telefactor, West Warwick, R.I.) was placed in the mouth to serve as the reference electrode, and a silver-silver chloride electrode (Grass-Telefactor, West Warwick, R.I.) was placed in the tail to serve as the ground electrode. Recordings were performed at a wide range of stimulus intensities (3.3 to 1.0 log cd*s/m2 in 0.3-log unit increments) in dark-adapted (scotopic) condition. The response at each intensity was an average of at least five trials. Signals were band-pass filtered from 1 to 100 Hz and were acquired at 1 kHz. The duration of the ERG recording session was approximately 30 minutes for each animal.
- The flattened retinas were made permeable in ice-cold 70% vol/vol ethanol for 20 minutes and then in PBS/1% Triton X-100 for 30 minutes. Retinas were incubated with AlexaFluor 568-conjugated Griffonia simplicifolia isolectin B4 (5 μg/mL; Invitrogen-Molecular Probes, Eugene, Oreg.) in 1×PBS overnight at 4° C. for staining of the vasculature. Then retinas were rinsed three times in 1×PBS for 10 min each and mounted in antifade medium (Prolong Antifade Kit (P7481); Invitrogen-Molecular Probes) and was sealed with the coverslip. Images of retinal vasculature were captured with fluorescence imaging and confocal microscopy (Live Cell TIRF System and MR confocal microscope; Singapore Bio Imaging Centre-Nikon Imaging Centre, Singapore).
- Our study result showed that Angio-3 peptide significantly attenuates the retinal angiogenesis in KIMBA mice (
FIG. 1A-D ). Eylea (positive control) is only effective for 4 weeks post treatment when commenced treatment at 6 weeks of old Kimba mice via IVT. However, Angio-3 (test peptide) is effective for up to 16 weeks post treatment (FIG. 2A-D ). This data indicates the long duration of Angio-3 efficacy in mice model Laser-induced mice model study demonstrated that Angio-3 peptide significantly attenuates the retinal and choroidal angiogenesis via IN route by single dose till week 10 (FIG. 3A-C ). The systemic route did not affect the natural wound healing process, menstrual cycle and behavioural change, which shows that Angio-3 is safe to given via IV route. Angio-3 also significantly attenuates the retinal and choroidal angiogenesis than anti-VEGF via IVT route (FIGS. 4A-B ). Angio-3 also shows significantly attenuates the retinal and choroidal angiog than anti-VEGF via sub-lingual route (FIGS. 5A-C ). In addition, our study shows that Angio-3 could be a potential long acting anti-angiogenic for retinal and choroidal angiogenesis diseases (FIGS. 2 and 3 ). - This peptide can be administered as intravenous or via IVT application for prevention or treatment of retinal angiogenic diseases. Our animal model study result confirms that Angio-3 is a long-acting anti-VEGF, which has potential benefit than current drug in the market.
- In B6J mice, single intravitreous (IVT) injection of 100 ng, 1 μg, 5 μg PEP-Q, PEP-N (modified Angio-3), Angio-3 and Eylea were executed and this was tested in Prevention mode (before laser) Method of Llser induced CNV model and injection was described as above.
- The study result showed that chemical modified angio-3 peptides: PEP-N and PEP-Q peptide significantly attenuates the choroidal angiogenesis in laser-induced CNV mice via single intravitreal injection at
dose 100 ng, 1 μg, and 5 μg. (FIGS. 11A-B ). The original Angio-3 (100 ng and 1 μg) and positive control Eylea® at the same dose (100 ng, 1 μg, and 5 μg) also shows superior efficacy that is similar to PEP-Q and PEP-N (FIG. 11 ; Table 2). PEP-Q and PEP-N could be a potential long acting anti-angiogenic for retinal and choroidal angiogenic diseases. -
TABLE 2 Summary of PEP-N, PEP-Q, Angio-3 and Eylea ® on Area of Leakage Area of Leakage (Mean) Groups Week 1 Week 4% Reduction Vehicle control 14738.20 9110.67 0% PEP- N 100 ng 11287.40 2237.13 42.00% 1 μg 12808.95 2402.54 43.06% 5 μg 8251.43 749.71 52.73% PEP- Q 100 ng 9987.09 1283.52 48.96% 1 μg 13444.41 1271.30 52.36% 5 μg 12839.27 742.03 56.04 % Eylea 100 ng 10273.37 3433.52 28.40% 1 μg 12502.09 3005.85 37.77% 5 μg 11724.39 1834.08 46.17% Angio-3 100 ng 7404.61 3334.89 50.03% 1 μg 6214.08 2867.88 48.92% - This two Angio-3 peptides, PEP-Q and PEP-N, can be administered as intravitreal injection for prevention or treatment of retinal angiogenic diseases. The animal model study result confirmed that chemically-modified Angio-3 peptides, PEP-Q and PEP-N, are novel and has potentially greater benefit than current drugs on the market.
- 2000 HRMEC cells were seeded in 96-well plates in 100 μl of media and placed in a CO2 incubator at 37° C. To evaluate the effect the compounds have on VEGF-induced HRMEC proliferation, cells were treated with 10 ng/ml VEGF165 or 50 ng/ml VEGF165 in the presence of different concentrations of Angio-3 after serum starved in EBM-2 supplemented with 0.5% FBS overnight. 300 μg/ml Avastin was used as a positive control. Alamar-Blue assay was performed after 3 days of treatment.
- HRMEC cells were incubated with different concentrations of compounds in the presence or absence of VEGF165 for 3 days. Results showed that HRMEC proliferation was induced by 10 ng/ml and 50 ng/ml of VEGF165. 300 μg/ml Avastin was sufficient to inhibit VEGF induce proliferation. However, Angio-3 showed no effect on VEGF induced proliferation at all three concentrations tested (
FIGS. 12A and B). - Transwell migration assays were performed in a 24-well cells culture plate containing 8.0 μm pore size inserts. HRMEC cells were serum starved overnight prior of assay. The lower chamber were filled with EBM-2, EBM-2 supplemented with 50 ng/ml VEGF165 plus different concentrations of inhibitors. 1×105 Cells in EBM-2 were seeded in the upper chamber. Cells were allowed to migrate to the other side of membrane for overnight at 37° C. Cells on top of the membrane were wiped off and cells migrated to the other side were fixed and stained with 0.4% crystal violet. Cell numbers were counted under a 10× objective for 5 randomly selected fields.
- The results showed that HRMEC cells migration was strongly induce by VEGF165. Migration stimulated by VEGF was completely blocked by 300 μg/
ml Avastin 300 μg/ml. 300 μg/ml and 600 μg/ml Angio-3 also showed a moderate inhibitory effect on VEGF induced migration (FIGS. 13A-B ). -
Cold 50 μl matrigel GFR (BD Biosciences) was added into 96-well plates, and the plates were incubated at 37° C. for 1 h to allow gel formation. HRMEC (1×105/well) in EBM-2, EBM-2 supplemented with 50 ng/ml VEGF165 with or without different concentrations of Angio-3 were then plated on the matrigel, 300 μg/ml Avastin was used as a positive control. After overnight incubation, 5 randomly selected fields of the network growth area of the cells were photographed using an inverted phase contrast photomicroscope. Tube networks were quantified using Image J Angiogenesis Analyzer. - Effect of Angio-3 on VEGF induced HRMEC cells tube formation was examined and quantified in term of total tube length, number of junctions and number of loops.
FIG. 14 showed that VEGF induced endothelial cells tube formation network was strongly inhibited by all drug tested. -
FIGS. 15A and 15B show that Angio-3 induced human umbilical vein endothelial cells (HUVECs) apoptosis in the presence of both VEGF and bFGF.FIG. 15A showed Angio-3 induced HUVEC apoptosis in the presence of 20 ng/ml VEGF in a dose-dependent manner.FIG. 15B showed that Angio-3 induced HUVEC apoptosis in the presence of 20 ng/ml bFGF in a dose-dependent manner. * represents p<0.05, n=3. -
FIGS. 16A and 16B show that Angio-3 inhibited HUVEC proliferation stimulated by VEGF and bFGF.FIG. 16A shows Angio-3 suppressed HUVEC proliferation induced by 20 ng/ml VEGF in a dose-dependent manner.FIG. 16B shows Angio-3 suppressed HUVEC proliferation induced by 20 ng/ml bFGF in a dose-dependent manner. * represents p<0.05, n=3. -
FIGS. 17 A-D show Angio-3 inhibited VEGF and bFGF-induced EC migration and inhibits capillary network formation.FIGS. 17 A and 22 C show Angio-3 suppressed HUVEC chemotactic migration induced by 20 ng/ml VEGF in a dose-dependent manner. Migrated cells were stained with Hoechst, imaged and counted.FIGS. 17 B and 22 D show Angio-3 suppressed HUVEC chemotactic migration that was induced by 20 ng/ml bFGF in a dose-dependent manner. Migrated cells were stained with Hoechst, imaged and counted. -
FIG. 18 shows Angio-3 inhibited HUVEC capillary network formation on Matrigel. HUVECs were pre-incubated with increasing doses of Angio-3 for 30 min prior to seeding onto Matrigel and cultured under complete EC growth media. HUVEC tube formation was imaged after 6 h of incubation. Percentage area covered by HUVEC tubes were quantified as the level of tube formation. n=3; * represents significant reduction compared to control at P<0.05 by one-way ANOVA. -
FIGS. 19A, 19B and 19C show Angio-3 is a novel anti-permeability agent that can inhibit VEGF-induced vascular permeability (VP) with multiple endothelial cell types. InFIG. 19A , post-confluent HUVEC monolayers were treated with increasing concentrations of Angio-3 or medium alone. The results show that Angio-3 inhibited VEGF-induced permeability across confluent HUVECs in a dose-dependent manner without affecting the basal level permeability. In these experiments, post-confluent HUVEC monolayers were pre-treated with Angio-3 for 30 minutes prior to stimulation with 100 ng/ml VEGF. InFIG. 19B , Post-confluent HMVEC monolayers were treated with increasing concentrations of Angio-3 or medium alone. The results show that Angio-3 inhibited VEGF-induced permeability across confluent human dermal microvascular endothelial cells (HMVECs) in a dose-dependent manner without affecting the basal level permeability. InFIG. 19C , post-confluent HREC monolayers were treated with Angio-3 and VEGF for 3 h. The results show that Angio-3 inhibited VEGF-induced permeability across confluent human retinal endothelial cells (HRECs) in a dose-dependent manner without affecting the basal level permeability. * represents p<0.05, n=3. -
FIGS. 20A and 20B show Angio-3 inhibited local VEGF-induced dermal vascular permeability in mice. InFIG. 20A , Angio-3 was administered via intradermal injection to mice and the results show that Angio-3 inhibited VEGF-induced dermal permeability in a dose-dependent manner within 15 min. The dermal permeability was visualized by Evans blue dye extravasation. InFIG. 20B , dye extravasation was quantified by formamide extraction of the dye and measuringOD 610. n=5 animals per group, * represent significantly increased as compared with the simultaneous control at p<0.05. -
FIG. 21 shows Angio-3 prevented VEGF-induced dissociation of Vascular endothelial (“VE”)-cadherin from Adherens junctions (AJs) on HUVECs. Confluent HUVECs were stimulated with 100 ng/ml VEGF to induce VE-cadherin dissociation from the AJs. The HUVECs confluent monlayes were pre-treated by 100 μM Angio-3 prior to VEGF stimulation. VE-cadherin is stained by antibody and DAPI was used to counter-stain the nucleus. Angio-3 can interferes with the ability of VEGF to induce VE-cadherin dissociation from AJs. -
FIG. 22 shows Angio-3 suppressed VEGF-induced dissociation of tight junction (TJ) proteins ZO-1 and ZO-2 from TJs in HUVECs. HUVEC cells Cells were treated as described above and stained with an ZO-1 antibody or a ZO-2 antibody, and counter-stained with DAPI to show the nucleus. The results show that VEGF induces the TJ protein ZO-1 and ZO-2 to dissociate from the TJs of confluent HUVEC monolayers. Pre-treatment of Angio-3 (100 μM) can suppress this VEGF function. -
FIG. 23 shows Angio-3 suppressed VEGF-induced actin stress fiber formation in HUVECs. However, in the absence of VEGF, Angio-3 promoted cortical actin fiber formation. - Eight-week-old KIMBA mice that overexpress hVEGF were dark-adapted overnight (for at least 12 hours) and all the procedures were carried out under dim red light. Mice were anesthetized with a combination of ketamine (20 mg/kg body weight) and xylazine (2 mg/kg body weight). Pupils were dilated with a topical administration of 1% tropicamide (Alcon Laboratories, Inc., Fort Worth, Tenn. USA) and 2.5% phenylephrine (Bausch and Lomb Pharmaceuticals, Inc., Tampa, Fla., USA) ophthalmic solutions.
- Animals were placed in ERG recording table with body temperature controller for ERG recordings. Electroretinograms were recorded (Espion; Diagnosys LLC, Lowell, Mass., USA) with corneal monopolar electrodes. A goldcup electrode was placed in the mouth to serve as the reference electrode, and a silver-silver chloride electrode (Grass-Telefactor, West Warwick, R.I., USA) was placed in the tail to serve as the ground electrode. Recordings were performed at a wide range of stimulus intensity (−3.0 to 1.0 log cd·s/m2) in dark-adapted (scotopic) condition. The response ateach flash intensity was an average of at least five trials. Signals were band-pass filtered from 1 to 100 Hz and were acquired at 1 kHz.
- ERG was recorded from 8 weeks old to 24 weeks old of mice in untreated group (naïve group). In Angio-3 IVT treated group, ERG was recorded at 8 weeks old as baseline (BL) and then 6 and 12 weeks post treatment. 2nd IVT was given at 12 weeks after 1st treatment and then followed for 8 weeks post treatment. Student's t-test was used to compare data between two groups; P<0.05 was considered to be significant. The results are shown in
FIG. 24 . The untreated mice has no response of both a and b-waves after 12 weeks of age. Angio-3 increased the a and b-wave responses for 6 weeks post treatment and then again increased the response for 20 weeks with second dose. This result shows that Angio-3 is rescuing the retinal function in KIMBA mice. - A laser-induced choroidal neovascularization (CNV) model was developed and validated in Cynomolgus monkeys as experimental model of wet AMD. The aim was to differentiate efficacy and dose response of test peptide from Eylea (clinical compound). 5 groups of 5 male Cynomolgus monkeys were used in this study. 3 groups were dosed IVT with 2 mg Angio-3; PeptideQ (SEQ ID NO:4) and Eylea® (
dose volume 50 μL) respectively. 1 group of 5 monkeys received 4 mg of PeptideQ. 1 group was served as laser control without any drug treatment. Both eyes were injected by a single IVT injection of the drugs atDay 14 after application of laser. The development of active CNV was assessed by fluorescein angiography, atDay 14 the baseline degree of neovascularization and leakiness were measured and the final fluorescein angiography assessment was performed onDay 28. Leakage area was quantified by ImageJ software. The laser volume was quantified by Spectralis-Heidelberg software using SD-OCT images. The results are shown inFIGS. 25A-F . - In this intervention study, no change in lesion severity was observed for the laser control and the change in lesion severity and laser area was significantly different for all drug treated groups as compared with control (analysis of variance [ANOVA] followed by Tukey's multiple comparison, @=p<0.05 compared with Control). Eylea shows the superior efficacy as compared to test peptides. However, Pep-Q shows dose dependent efficacy and higher dose efficacy close to Eylea.
- Mice were anesthetized with the combination of 80 mg/kg ketamine and 5 mg/kg xylazine. One drop of 1% xylocaine was applied to the corneal surface for local analgesia. Round piece of filter paper, approximately 2 mm in diameter was soaked in a solution of 1 M NaOH. A piece of NaOH soaked filter paper was picked by sterile forceps. NAOH soaked filter paper was placed on the central cornea under microscope to ensure properly placing the filter paper. Left it for 30 sec to generate an acute alkali-burn of approximately 2×2 mm2 in area. Filter paper was removed and then gently flushed the eye with 10 ml of 1×PBS twice to wash away residual 1 M NaOH. Only one eye of the mouse was injured and the other serving as a control. A drop of 1× Peptide Q (1% solution as test compound) or a vehicle control consisting of PBS was topically applied to the cornea. Repeated application occurred 3×/day for 7 days. At end point, clinical assessment was done as stated below and eyes were enucleated for corneal flat mount.
- A daily examination of the mice in a blinded fashion was performed under a surgical microscope and score corneal neo-vascularization (NV) was based on corneal opacity, NV and vessel size. Two observers were scored and record a final score that was the average of the two. Score corneal opacity on a scale of 0-4. 0=completely clear; 1=slightly hazy, iris and pupil easily visible; 2=slightly opaque, iris and pupil still detectable; 3=opaque, pupils hardly detectable; and 4=completely opaque with no view of the pupil. Score NV on a scale of 0-3. 0=no neovessels; 1=neovessels at the corneal limbus; 2=neovessels spanning the corneal limbus and approaching the corneal center; 3=neovessels spanning the corneal center. Score vessel size on a scale of 0-3. 0=no neovessels; 1=neovessels detectable under surgical microscope; 2=neovessels easily seen under surgical microscope; 3=neovessels easily seen without the microscope. Images were captured using surgical microscope camera and slitlamp biomicroscopy. The results are shown in
FIGS. 26 and 27 . Peptide Q treated eyes had significantly reduced corneal NV area as compared to vehicle control eyes. - Two (2)-mm trephine was used to mark the wound size. Epithelium, basement membrane and some stromal layers were removed by peeling using forceps. Fluorescein staining to the wounded area of cornea was done from
day 0 to Day 5 (n=6 mice per group from 2 independent experiments). Gentle and meticulous approach when wounding and handling mouse cornea, fluorescein was diluted, slit lamp images had to be taken within a few seconds after staining. The wound area was quantified by ImageJ software. Student's t-test was used to compare data between two groups; P<0.05 was considered to be significant. The results are shown inFIGS. 28A and 28B . Angio-3 didn't adversely affect the normal wound healing process. - It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, sequence accession numbers, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
Claims (14)
1.-24. (canceled)
25. A method of treating a retinal angiogenic disease in a subject comprising:
(a) selecting a subject with retinal angiogenic disease not responsive to anti-VEGF therapy; and
(b) administering to the subject a composition comprising a peptide consisting of the sequence Thr Pro His Thr His Gin Xaa Thr Pro Glu (SEQ ID NO:4) wherein administration treats the retinal angiogenic disease in the subject.
26. The method of claim 25 , wherein the composition comprises 2 to 50 mg/kg Bwt of the peptide and is administered by intravenous injection.
27. The method of claim 25 , wherein the composition comprises 0.1 μg/kg to 2 mg/kg Bwt of the peptide and is administered by intravitreal injection.
28. The method of claim 25 , wherein the composition comprises 2 to 10 mg/kg Bwt of the peptide and is administered orally.
29. The method of claim 25 , wherein the composition is administered via either intravenous (IV) or intravitreal (IVT) route at least once every 4 to 10 weeks.
30. The method of claim 25 , wherein the composition is administered orally at least once daily for 1 to 2 weeks at intervals of 6 months.
31. The method of claim 25 , wherein the anti-VEGF therapy is an anti-VEGF antibody.
32. The method of claim 25 , wherein the subject has age-related macular degeneration, retinopathy, or vascular occlusion.
33. The method of claim 25 , wherein the subject has diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, or corneal neovascularization.
34. The method of claim 25 , wherein the subject is a human.
35. The method of claim 25 , wherein the composition is formulated for intravenous administration.
36. The method of claim 25 , wherein the composition is formulated for intravitreal injection.
37. The method of claim 25 , wherein the composition is formulated for oral administration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/525,793 US20220175876A1 (en) | 2017-08-31 | 2021-11-12 | Angio-3 for treatment of retinal angiogenic diseases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762553051P | 2017-08-31 | 2017-08-31 | |
PCT/IB2018/056685 WO2019043649A2 (en) | 2017-08-31 | 2018-08-31 | Angio-3 for treatment of retinal angiogenic diseases |
US202016641978A | 2020-02-25 | 2020-02-25 | |
US17/525,793 US20220175876A1 (en) | 2017-08-31 | 2021-11-12 | Angio-3 for treatment of retinal angiogenic diseases |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/641,978 Continuation US11266710B2 (en) | 2017-08-31 | 2018-08-31 | Angio-3 for treatment of retinal angiogenic diseases |
PCT/IB2018/056685 Continuation WO2019043649A2 (en) | 2017-08-31 | 2018-08-31 | Angio-3 for treatment of retinal angiogenic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220175876A1 true US20220175876A1 (en) | 2022-06-09 |
Family
ID=65525123
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/641,978 Active US11266710B2 (en) | 2017-08-31 | 2018-08-31 | Angio-3 for treatment of retinal angiogenic diseases |
US17/525,793 Abandoned US20220175876A1 (en) | 2017-08-31 | 2021-11-12 | Angio-3 for treatment of retinal angiogenic diseases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/641,978 Active US11266710B2 (en) | 2017-08-31 | 2018-08-31 | Angio-3 for treatment of retinal angiogenic diseases |
Country Status (7)
Country | Link |
---|---|
US (2) | US11266710B2 (en) |
EP (1) | EP3675889A4 (en) |
JP (1) | JP2020532586A (en) |
CN (1) | CN111344002A (en) |
AU (1) | AU2018326835A1 (en) |
SG (1) | SG11202001595SA (en) |
WO (1) | WO2019043649A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5902790A (en) * | 1995-10-03 | 1999-05-11 | Cytran, Inc. | Pharmaceutical angiostatic dipeptide compositions and method of use thereof |
US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
ATE368051T1 (en) * | 1995-04-26 | 2007-08-15 | Childrens Medical Center | ANGIOSTATIN FRAGMENTS AND METHODS OF USE THEREOF |
US7317003B2 (en) | 1998-09-04 | 2008-01-08 | National University Of Singapore | Small peptides having anti-angiogenic and endothelial cell inhibition activity |
SG87828A1 (en) | 1999-09-03 | 2002-04-16 | Univ Singapore | Small peptides having potent anti-angiogenic activity |
AU2003244516A1 (en) * | 2002-02-07 | 2003-09-02 | Novozymes Delta Limited | Hiv inhibiting proteins |
AU2003225910A1 (en) * | 2002-03-20 | 2003-10-08 | Johns Hopkins University | Raav vector compositions and methods for the treatment of choroidal neovascularization |
CN101942012A (en) | 2009-07-08 | 2011-01-12 | 上海市第一人民医院 | Polypeptide for preventing and treating angiogenesis and application thereof |
CA2796312C (en) * | 2010-05-28 | 2020-11-03 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis |
CA2891686A1 (en) | 2012-12-18 | 2014-06-26 | Novartis Ag | Compositions and methods that utilize a peptide tag that binds to hyaluronan |
SG11201602889TA (en) * | 2013-10-28 | 2016-05-30 | Bicycle Therapeutics Ltd | Novel polypeptides |
-
2018
- 2018-08-31 SG SG11202001595SA patent/SG11202001595SA/en unknown
- 2018-08-31 CN CN201880056661.2A patent/CN111344002A/en active Pending
- 2018-08-31 WO PCT/IB2018/056685 patent/WO2019043649A2/en unknown
- 2018-08-31 AU AU2018326835A patent/AU2018326835A1/en not_active Abandoned
- 2018-08-31 JP JP2020533879A patent/JP2020532586A/en active Pending
- 2018-08-31 EP EP18851201.6A patent/EP3675889A4/en active Pending
- 2018-08-31 US US16/641,978 patent/US11266710B2/en active Active
-
2021
- 2021-11-12 US US17/525,793 patent/US20220175876A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2019043649A2 (en) | 2019-03-07 |
CN111344002A (en) | 2020-06-26 |
US20200246417A1 (en) | 2020-08-06 |
SG11202001595SA (en) | 2020-03-30 |
JP2020532586A (en) | 2020-11-12 |
EP3675889A4 (en) | 2021-05-12 |
EP3675889A2 (en) | 2020-07-08 |
AU2018326835A1 (en) | 2020-03-26 |
US11266710B2 (en) | 2022-03-08 |
WO2019043649A3 (en) | 2019-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220175876A1 (en) | Angio-3 for treatment of retinal angiogenic diseases | |
NO20121169A1 (en) | Pharmacological vitreolysis | |
US11918577B2 (en) | Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases | |
CA2936146A1 (en) | Methods and compositions for preventing or treating dominant optic atrophy | |
Vecino et al. | Glaucoma animal models | |
KR20220054598A (en) | Peptides for the treatment of non-exudative macular degeneration and other eye diseases | |
WO2005118799A1 (en) | Ovine hyaluronidase | |
US20240067949A1 (en) | Compositions and methods for the treatment of neuronal injuries | |
KR20200137499A (en) | Peptide for treating or preventing of glaucoma and use thereof | |
US8722015B2 (en) | Compositions and methods for treatment of angiogenesis-associated ocular disorders | |
Wu et al. | The multifunctional human ocular melanocortin system | |
EP3517133A2 (en) | Pharmaceutical composition containing mtor inhibitor for treating macular degeneration | |
US20210330735A1 (en) | Compositions and methods for the treatment of traumatic optic neuropathy | |
Inagaki et al. | Creation of retinal vein occlusion model in cynomolgus monkeys and determination of its pathological features | |
US20230077811A1 (en) | Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation | |
US20170173111A1 (en) | Semaphorin 3c variants, compositions comprising said variants and methods of use thereof in treating eye diseases | |
KR20220051791A (en) | Composition for preventing or treating macular degeneration comprising Fas signaling-blocking peptide | |
Jones | The Role of Fibrillin-1 in Eye Development and Disease | |
Ghoz | Ocular neovascularization: pathological changes in cornea, conjunctiva and retina | |
CA3154499A1 (en) | Compositions and methods for rescuing retinal and choroidal structure and function | |
CN115942951A (en) | NGF variants, preparation, compositions and therapeutic uses | |
Ferrer et al. | Ophthalmic therapeutics: new basic research and clinical studies | |
Fernandez-Lloris | Association for Research in Vision and Ophthalmology (ARVO)-2015 Annual Meeting. Denver, Colorado, USA-May 3-7, 2015 | |
Abd-El-Barr et al. | 2008 E-ABSTRACT FIRST AUTHOR INDEX | |
EP3096769A1 (en) | Therapeutic use of vegfr-3 ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |